EA

Euroapi SASPAR Euroapi Stock Report

Last reporting period 30 Jun, 2024

Updated 29 Oct, 2024

Last price

Market cap $B

1.422

Small

Exchange

XPAR - Euronext Paris

EAPI.PA Stock Analysis

EA

Uncovered

Euroapi SAS is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-20/100

Low score

Market cap $B

1.422

Dividend yield

Shares outstanding

94.027 B

EUROAPI SA operates as a manufacturer and supplier of active pharmaceutical ingredient solutions for healthcare companies. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2022-05-06. The firm is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc. ), analgesics, etc. The firm also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. The company has production sites located in France, the United Kingdom, Germany, Italy and Hungary.

View Section: Eyestock Rating